| Year |
Citation |
Score |
| 2024 |
Rezaee ME, Macura KJ, Trock BJ, Herati A, Pavlovich CP, Han M, Stoianovici D. Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores. Prostate Cancer and Prostatic Diseases. PMID 38184758 DOI: 10.1038/s41391-023-00780-1 |
0.351 |
|
| 2023 |
Rezaee ME, Pallauf M, Fletcher SA, Han M, Pavlovich CP, Cornelia Ding CK, Epstein JI, Allaf ME, Trock BJ, Singla N. Risk of Biochemical Recurrence in Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension Treated with Radical Prostatectomy. The Journal of Urology. 101097JU000000000000. PMID 38109699 DOI: 10.1097/JU.0000000000003825 |
0.414 |
|
| 2023 |
Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O'Brien VP, Isaacs WB, Epstein JI, De Marzo AM, ... Trock BJ, et al. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. The Journal of Pathology. PMID 37850574 DOI: 10.1002/path.6216 |
0.386 |
|
| 2023 |
de la Calle CM, Jing Y, Mamawala MM, Landis P, Macura KJ, Trock BJ, Epstein JI, Sokoll LJ, Pavlovich CP. Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification. Urologic Oncology. 41: 455.e1-455.e6. PMID 37722985 DOI: 10.1016/j.urolonc.2023.08.011 |
0.316 |
|
| 2022 |
Trabzonlu L, Pienta KJ, Trock BJ, De Marzo AM, Amend SR. Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer. The Prostate. PMID 36372998 DOI: 10.1002/pros.24459 |
0.327 |
|
| 2022 |
de la Calle CM, Mamawala MM, Landis P, Macura KJ, Trock BJ, Epstein JI, Pavlovich CP. Clinical Significance of Perineural Invasion in Men with Grade Group 1 Prostate Cancer on Active Surveillance. The Journal of Urology. 101097JU000000000000. PMID 36073925 DOI: 10.1097/JU.0000000000002963 |
0.383 |
|
| 2022 |
Trock BJ, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, Vidal I, Glavaris SA, Guner G, Ertunc O, Kulac I, Baena Del Valle JA, Jones T, Han M, Partin AW, et al. Cell Cycle Progression Score, But Not PTEN Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-Risk Prostate Cancer in Men Treated with and without Salvage Radiotherapy. The Journal of Urology. 101097JU000000000000. PMID 36006048 DOI: 10.1097/JU.0000000000002922 |
0.388 |
|
| 2022 |
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, et al. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. European Urology Open Science. 41: 126-133. PMID 35813247 DOI: 10.1016/j.euros.2022.05.012 |
0.386 |
|
| 2022 |
Kensler KH, Awasthi S, Alshalalfa M, Trock BJ, Freedland SJ, Freeman MR, You S, Mahal BA, Den RB, Dicker AP, Karnes RJ, Klein EA, Lal P, Liu Y, Davicioni E, et al. Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. European Urology Open Science. 40: 19-26. PMID 35638091 DOI: 10.1016/j.euros.2022.03.014 |
0.307 |
|
| 2022 |
Reyes DK, Trock BJ, Tran PT, Pavlovich CP, Deville C, Allaf ME, Greco SC, Song DY, Bivalacqua TJ, Han M, Partin AW, Sartor AO, Rowe SP, Pienta KJ. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Medical Oncology (Northwood, London, England). 39: 63. PMID 35478055 DOI: 10.1007/s12032-022-01662-7 |
0.343 |
|
| 2022 |
Beckmann KR, Bangma CH, Helleman J, Bjartell A, Carroll PR, Morgan T, Nieboer D, Santaolalla A, Trock BJ, Valdagni R, Roobol MJ. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. The Prostate. PMID 35254666 DOI: 10.1002/pros.24330 |
0.393 |
|
| 2022 |
Ruder S, Gao Y, Ding Y, Bu P, Miles B, De Marzo A, Wheeler T, McKenney JK, Auman H, Fazli L, Simko J, Coll AH, Troyer DA, Carroll PR, Gleave M, ... ... Trock B, et al. Development and Validation of a Quantitative Reactive Stroma Biomarker (qRS) for Prostate Cancer Prognosis. Human Pathology. PMID 35176252 DOI: 10.1016/j.humpath.2022.01.009 |
0.352 |
|
| 2022 |
Ouellet V, Erickson A, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, ... ... Trock BJ, et al. The Movember Global Action Plan 1 (GAP1) - Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35131885 DOI: 10.1158/1055-9965.EPI-21-0600 |
0.331 |
|
| 2021 |
Beckmann K, Santaolalla A, Helleman J, Carroll P, Ha Chung B, Shiong Lee L, Perry A, Rubio-Briones J, Sugimoto M, Trock B, Valdagni R, Dasgupta P, Van Hemelrijck M, Elhage O. Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. European Urology Open Science. 34: 47-54. PMID 34934967 DOI: 10.1016/j.euros.2021.09.012 |
0.384 |
|
| 2021 |
Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, et al. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. Jama Network Open. 4: e2115312. PMID 34196715 DOI: 10.1001/jamanetworkopen.2021.15312 |
0.364 |
|
| 2021 |
Vidal I, Zheng Q, Hicks JL, Chen J, Platz EA, Trock BJ, Kulac I, Baena-Del Valle JA, Sfanos KS, Ernst S, Jones T, Maynard JP, Glavaris SA, Nelson WG, Yegnasubramanian S, et al. GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. Plos One. 16: e0241934. PMID 34191807 DOI: 10.1371/journal.pone.0241934 |
0.378 |
|
| 2021 |
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV. Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003714. PMID 34086480 DOI: 10.1200/JCO.20.03714 |
0.343 |
|
| 2021 |
Marshall CH, Chen Y, Kuo C, Cullen J, Jiang J, Rosner I, Markowski M, McLeod DG, Trock BJ, Eisenberger MA. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. The Journal of Urology. 101097JU000000000000. PMID 34003011 DOI: 10.1097/JU.0000000000001797 |
0.386 |
|
| 2021 |
Stavrinides V, Papageorgiou G, Danks D, Giganti F, Pashayan N, Trock B, Freeman A, Hu Y, Whitaker H, Allen C, Kirkham A, Punwani S, Sonn G, Barratt D, Emberton M, et al. Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. Prostate Cancer and Prostatic Diseases. PMID 33958731 DOI: 10.1038/s41391-021-00373-w |
0.315 |
|
| 2021 |
Guest C, Harris R, Sfanos KS, Shrestha E, Partin AW, Trock B, Mangold L, Bader R, Kozak A, Mclean S, Simons J, Soule H, Johnson T, Lee WY, Gao Q, et al. Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. Plos One. 16: e0245530. PMID 33596212 DOI: 10.1371/journal.pone.0245530 |
0.348 |
|
| 2021 |
Yoon J, Kim M, Posadas EM, Freedland SJ, Liu Y, Davicioni E, Den RB, Trock BJ, Karnes RJ, Klein EA, Freeman MR, You S. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer and Prostatic Diseases. PMID 33531653 DOI: 10.1038/s41391-021-00325-4 |
0.334 |
|
| 2020 |
Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE, Siddiqui J, Kunju LP, Botbyl R, Chopra Z, Pandian B, Eyrich NW, Longton G, Zheng Y, Palapattu GS, et al. Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. The Journal of Urology. 101097JU000000000000. PMID 33080150 DOI: 10.1097/JU.0000000000001430 |
0.32 |
|
| 2020 |
Giganti F, Stabile A, Stavrinides V, Osinibi E, Retter A, Orczyk C, Panebianco V, Trock BJ, Freeman A, Haider A, Punwani S, Allen C, Kirkham A, Emberton M, Moore CM. Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. European Radiology. PMID 33000302 DOI: 10.1007/s00330-020-07256-z |
0.325 |
|
| 2020 |
Kaur H, Salles DC, Murali S, Hicks JL, Nguyen M, Pritchard CC, De Marzo AM, Lanchbury JS, Trock BJ, Isaacs WB, Timms KM, Antonarakis ES, Lotan TL. Genomic and Clinical-Pathologic Characterization of -deficient Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32694154 DOI: 10.1158/1078-0432.Ccr-20-0764 |
0.451 |
|
| 2020 |
Stavrinides V, Giganti F, Trock B, Punwani S, Allen C, Kirkham A, Freeman A, Haider A, Ball R, McCartan N, Whitaker H, Orczyk C, Emberton M, Moore CM. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. European Urology. PMID 32360049 DOI: 10.1016/J.Eururo.2020.03.035 |
0.409 |
|
| 2020 |
Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Pra AD, Mahal BA, et al. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases. PMID 32231245 DOI: 10.1038/S41391-020-0226-2 |
0.48 |
|
| 2020 |
Su ZT, Mamawala MK, Landis PK, Kuczler M, Gorin MA, Pavlovich CP, Trock BJ. Pd62-05 Association Of Diet And Nutrient Intake With Biopsy Upgrading In Men With Prostate Cancer On Active Surveillance The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000979.05 |
0.419 |
|
| 2020 |
Stavrinides V, Giganti F, Trock B, Punwani S, Clare A, Kirkham A, Freeman A, Haider A, Ball R, McCartan N, Grey A, Whitaker H, Orczyk C, Emberton M, Moore C. Mp23-20 Low Psa Density At Baseline Is Associated With Prolonged Mri-Based Active Surveillance For Gleason 6 Prostate Cancer The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000856.020 |
0.456 |
|
| 2020 |
Patel H, Faisal F, Trock B, Joice G, Schwen Z, Pierorazio P, Johnson M, Bivalacqua T, Han M, Gorin M, Carter HB, Partin A, Pavlovich C, Allaf M. Pd13-06 Effect Of Pharmacologic Prophylaxis On Venous Thromboembolism After Radical Prostatectomy: The Preventer Randomized Clinical Trial The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000847.06 |
0.419 |
|
| 2019 |
Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer. PMID 31639200 DOI: 10.1002/Cncr.32557 |
0.489 |
|
| 2019 |
Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, Neal TO, Chapman C, Harb R, Milman Y, Trock BJ, Drake CG, Antonarakis ES. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 31611635 DOI: 10.1038/S41391-019-0176-8 |
0.478 |
|
| 2019 |
Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer. PMID 31530439 DOI: 10.1016/J.Clgc.2019.08.002 |
0.501 |
|
| 2019 |
Maruf M, Manyevitch R, Michaud J, Jayman J, Kasprenski M, Zaman MH, Benz K, Eldridge M, Trock B, Harris KT, Wu WJ, Di Carlo HN, Gearhart JP. Urinary Continence Outcomes in Classic Bladder Exstrophy: A Long-Term Perspective. The Journal of Urology. 101097JU000000000000. PMID 31437120 DOI: 10.1097/Ju.0000000000000505 |
0.3 |
|
| 2019 |
van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, et al. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology. 2: 333-336. PMID 31200849 DOI: 10.1016/J.Euo.2018.08.017 |
0.491 |
|
| 2019 |
Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, ... ... Trock BJ, et al. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. PMID 30773341 DOI: 10.1016/J.Ccell.2019.01.008 |
0.312 |
|
| 2019 |
Trock BJ, Rajamani S, Vidal I, Glavaris S, Jones T, Han M, Partin AW, Cohen T, Stone S, Marzo AMD. Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16575 |
0.43 |
|
| 2019 |
Marshall CH, Fu W, Wang H, Trock BJ, Eisenberger MA. Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis. Journal of Clinical Oncology. 37: 5016-5016. DOI: 10.1200/Jco.2019.37.15_Suppl.5016 |
0.467 |
|
| 2019 |
Dave C, Khalaf A, Trock B, Burnett A. Mp27-15 Neurogenic Bladder Is An Independent Risk Factor For Complications Associated With Inflatable Penile Prosthesis Placement The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555700.77145.88 |
0.301 |
|
| 2019 |
Gupta* M, Srivastava A, Patel H, Reyes D, Trock B, Tran P, Allaf M, Bivalacqua T, Carter H, Ross A, Partin A, Schaeffer E, Pienta K, Pavlovich C. MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555599.69863.27 |
0.475 |
|
| 2019 |
Marshall CH, Chen Y, Cullen J, Rosner I, Markowski M, Trock B, Eisenberger M. Overall survival (OS) and metastasis-free survival (MFS) in men with biochemically relapsed (BCR) prostate cancer after radical prostatectomy (RP) managed with deferred androgen deprivation treatment (ADT): A combined Johns Hopkins and CPDR study Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz248.009 |
0.475 |
|
| 2018 |
Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, et al. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. Jco Precision Oncology. 2018. PMID 30761387 DOI: 10.1200/PO.18.00036 |
0.347 |
|
| 2018 |
Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. The Annals of Applied Statistics. 12: 1773-1795. PMID 30627300 DOI: 10.1214/17-Aoas1130 |
0.421 |
|
| 2018 |
Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, ... ... Trock BJ, et al. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases. PMID 30542054 DOI: 10.1038/S41391-018-0101-6 |
0.501 |
|
| 2018 |
Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression is Associated with Lethal Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30420441 DOI: 10.1158/1055-9965.Epi-18-0667 |
0.458 |
|
| 2018 |
Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, et al. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 30367117 DOI: 10.1038/S41391-018-0103-4 |
0.364 |
|
| 2018 |
Guedes LB, Morais CL, Fedor H, Hicks J, Gurel B, Melamed J, Lee P, Gopalan A, Knudsen BS, True LD, Scher HI, Fine SW, Trock BJ, De Marzo AM, et al. Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of Pathology & Laboratory Medicine. PMID 30295067 DOI: 10.5858/Arpa.2018-0068-Oa |
0.476 |
|
| 2018 |
Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL. PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer and Prostatic Diseases. PMID 30279579 DOI: 10.1038/S41391-018-0093-2 |
0.489 |
|
| 2018 |
Druskin SC, Mamawala M, Tosoian JJ, Epstein JI, Pavlovich CP, Carter HB, Trock BJ. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance. The Journal of Urology. PMID 30114397 DOI: 10.1016/J.Juro.2018.08.023 |
0.489 |
|
| 2018 |
Bismar TA, Hegazy S, Feng Z, Yu D, Donnelly B, Palanisamy N, Trock BJ. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. Journal of Cancer Research and Clinical Oncology. 144: 2117-2125. PMID 30101374 DOI: 10.1007/S00432-018-2730-5 |
0.476 |
|
| 2018 |
Alshalalfa M, Karnes RJ, Sharma V, Choeurng V, Al-Deen Ashab H, Erho N, Trock BJ, Ross AE, Yousefi K, Tsai HK, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, et al. Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29760221 DOI: 10.1158/1078-0432.Ccr-17-2745 |
0.478 |
|
| 2018 |
Partin AW, VAN Criekinge W, Trock BJ, Epstein JI, VAN Neste L. CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. Transactions of the American Clinical and Climatological Association. 127: 313-327. PMID 28066067 |
0.406 |
|
| 2018 |
Trock BJ, Karnes RJ, Claessens F, Davis JW, Haddad Z, Yousefi K, Davicioni E, Ross A. Validation of a genomic risk classifier to predict metastasis and prostate cancer-specific mortality in men with positive lymph nodes. Journal of Clinical Oncology. 36: 125-125. DOI: 10.1200/Jco.2018.36.6_Suppl.125 |
0.475 |
|
| 2018 |
Trock B, Karnes RJ, Claessens F, Davis J, Haddad Z, Yousefi K, Davicioni E, Ross A. PD60-06 VALIDATION OF A GENOMIC RISK CLASSIFIER TO PREDICT METASTASIS AND PROSTATE CANCER-SPECIFIC MORTALITY IN MEN WITH POSITIVE LYMPH NODES Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2818 |
0.412 |
|
| 2017 |
Anakwenze CP, Ntekim A, Trock B, Uwadiae IB, Page BR. Barriers to radiotherapy access at the University College Hospital in Ibadan, Nigeria Clinical and Translational Radiation Oncology. 5: 1-5. PMID 29594210 DOI: 10.1016/J.Ctro.2017.05.003 |
0.312 |
|
| 2017 |
Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Annals of Internal Medicine. PMID 29181514 DOI: 10.7326/M17-0548 |
0.474 |
|
| 2017 |
Ludwig WW, Feng Z, Trock BJ, Humphreys E, Walsh PC. Prostate specific antigen testing after radical prostatectomy: can we stop at 20 years? The Journal of Urology. PMID 28818527 DOI: 10.1016/J.Juro.2017.08.041 |
0.449 |
|
| 2017 |
Lange JM, Trock BJ, Gulati R, Etzioni R. A Framework for Treatment Decision Making at Prostate Cancer Recurrence. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X17711913. PMID 28564551 DOI: 10.1177/0272989X17711913 |
0.468 |
|
| 2017 |
Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, ... ... Trock BJ, et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology. PMID 28528811 DOI: 10.1016/J.Eururo.2017.05.009 |
0.424 |
|
| 2017 |
Druskin SC, Liu JJ, Young A, Feng Z, Dianat SS, Ludwig WW, Trock BJ, Macura KJ, Pavlovich CP. Prostate MRI prior to radical prostatectomy: effects on nerve sparing and pathological margin status. Research and Reports in Urology. 9: 55-63. PMID 28459044 DOI: 10.2147/Rru.S128499 |
0.429 |
|
| 2017 |
Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. European Urology. PMID 28400167 DOI: 10.1016/J.Eururo.2017.03.036 |
0.474 |
|
| 2017 |
Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LL, du Plessis M, Choeurng V, et al. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016702811. PMID 28358655 DOI: 10.1200/Jco.2016.70.2811 |
0.396 |
|
| 2017 |
Chalfin HJ, Feng Z, Trock BJ, Partin AW. Patterns of Pelvic Lymph Node Dissection at The Time of Radical Prostatectomy for Low-Risk Men. Urology. PMID 28232176 DOI: 10.1016/J.Urology.2017.01.037 |
0.381 |
|
| 2017 |
Epstein JI, Trock B, Han M. Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.11.006. European Urology. PMID 28108147 DOI: 10.1016/J.Eururo.2017.01.004 |
0.45 |
|
| 2017 |
Alam R, Patel HD, Riffon MF, Trock BJ, Uzosike A, Chang P, Wagner AJ, McKiernan JM, Allaf M, Pierorazio PM. Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses. Journal of Clinical Oncology. 35: 430-430. DOI: 10.1200/Jco.2017.35.6_Suppl.430 |
0.318 |
|
| 2017 |
Nguyen PL, Haddad Z, Lam LL, Ong K, Buerki C, Deheshi S, Yousefi K, Davicioni E, Tosoian JJ, Lotan TL, Feng FY, Trock BJ, Ross A, Klein EA. Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens. Journal of Clinical Oncology. 35: 4-4. DOI: 10.1200/Jco.2017.35.6_Suppl.4 |
0.477 |
|
| 2017 |
Markowski MC, Suzman D, Chen Y, Trock BJ, Cullen J, Feng Z, Antonarakis ES, Paller CJ, Han M, Partin AW, Eisenberger MA. PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP). Journal of Clinical Oncology. 35: 5075-5075. DOI: 10.1200/Jco.2017.35.15_Suppl.5075 |
0.502 |
|
| 2017 |
Sweeney C, Gerke T, Beltran H, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross A, Mucci L, Trock BJ. Association of loss of tumor suppressor ZFP36 with lethal prostate cancer. Journal of Clinical Oncology. 35: 5062-5062. DOI: 10.1200/Jco.2017.35.15_Suppl.5062 |
0.486 |
|
| 2017 |
Gerke T, Börnigen D, Beltran H, Tyekucheva S, Huttenhower C, Lee G, Trock B, Mucci L, Sweeney C. Abstract 4740: Loss of the tumor suppressor zinc finger protein-36 and risk of lethal prostate cancer Cancer Research. 77: 4740-4740. DOI: 10.1158/1538-7445.Am2017-4740 |
0.473 |
|
| 2017 |
Markowski M, Chen Y, Feng Z, Trock B, Cullen J, Suzman D, Antonarakis E, Paller C, Han M, Partin A, Eisenberger M. 818PPSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx370.035 |
0.49 |
|
| 2017 |
Druskin S, Mamawala M, Tosoian J, Carter HB, Trock B. Mp43-18 For Men On Active Surveillance For Prostate Cancer, Older Age At Diagnosis And At Radical Prostatectomy Portends Poor Outcomes The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1328 |
0.47 |
|
| 2017 |
Mamawala M, Landis P, Epstein J, Trock B, Carter HB. Mp43-15 Clinical Significance Of Detection Of Perineural Invasion (Pni) On A Surveillance Biopsy In Favorable Risk Men On Active Surveillance The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1325 |
0.365 |
|
| 2016 |
Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. European Urology. PMID 27876305 DOI: 10.1016/J.Eururo.2016.11.006 |
0.5 |
|
| 2016 |
Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M. The impact of downgrading from biopsy Gleason 7 to prostatectomy Gleason 6 on biochemical recurrence and prostate cancer-specific mortality. The Journal of Urology. PMID 27847296 DOI: 10.1016/J.Juro.2016.11.079 |
0.51 |
|
| 2016 |
Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, et al. Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. European Urology. PMID 27720532 DOI: 10.1016/J.Eururo.2016.09.041 |
0.41 |
|
| 2016 |
Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, et al. Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential. The Journal of Urology. PMID 27569435 DOI: 10.1016/J.Juro.2016.08.091 |
0.433 |
|
| 2016 |
Tosoian JJ, Almutairi F, Morais CL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. European Urology. PMID 27477529 DOI: 10.1016/J.Eururo.2016.07.026 |
0.443 |
|
| 2016 |
Mamawala MM, Rao K, Landis P, Epstein JI, Trock BJ, Tosoian JJ, Pienta KJ, Carter BH. Risk Prediction Tool for Grade Reclassification in Favorable-Risk Men on Active Surveillance. Bju International. PMID 27469419 DOI: 10.1111/Bju.13608 |
0.37 |
|
| 2016 |
Tosoian JJ, Chappidi M, Feng Z, Humphreys EB, Han M, Pavlovich CP, Epstein JI, Partin AW, Trock BJ. Prediction of Pathologic Stage Based on Clinical Stage, Serum PSA, and Biopsy Gleason Score: Partin Tables in the Contemporary Era. Bju International. PMID 27367645 DOI: 10.1111/Bju.13573 |
0.341 |
|
| 2016 |
Tosoian JJ, Trock BJ, Ballentine Carter H, Mamawala M. Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81. European Urology. PMID 27311363 DOI: 10.1016/J.Eururo.2016.05.037 |
0.423 |
|
| 2016 |
Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, Netto G, Partin AW, Trock BJ, Davicioni E, Schaeffer EM. SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at-risk, natural history radical prostatectomy cohort. The Journal of Urology. PMID 27238617 DOI: 10.1016/J.Juro.2016.05.092 |
0.509 |
|
| 2016 |
Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer and Prostatic Diseases. PMID 27136742 DOI: 10.1016/J.Ijrobp.2016.06.256 |
0.401 |
|
| 2016 |
Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27080984 DOI: 10.1038/Modpathol.2016.63 |
0.373 |
|
| 2016 |
Chalfin HJ, Liu JJ, Gandhi N, Feng Z, Johnson D, Netto GJ, Drake CG, Hahn NM, Schoenberg MP, Trock BJ, Scott AV, Frank SM, Bivalacqua TJ. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. Annals of Surgical Oncology. PMID 27012987 DOI: 10.1245/S10434-016-5193-4 |
0.34 |
|
| 2016 |
Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ. Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. Plos One. 11: e0146189. PMID 26731672 DOI: 10.1371/Journal.Pone.0146189 |
0.423 |
|
| 2016 |
Karnes J, Ashab HA, Trock BJ, Ross A, Tsai H, Tosoian JJ, Erho N, Choeurng V, Yousefi K, Haddad Z, Abdollah F, Klein EA, Nguyen PL, Feng FY, Dicker A, et al. Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure. Journal of Clinical Oncology. 34: 106-106. DOI: 10.1200/Jco.2016.34.2_Suppl.106 |
0.455 |
|
| 2016 |
Suzman DL, Cullen J, Trock BJ, Chen Y, Rosner IL, Feng Z, Antonarakis ES, Han M, Partin AW, Hurwitz L, Kuo H, McLeod DG, Eisenberger MA. PSA doubling time (PSADT) ≤6 months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16587 |
0.503 |
|
| 2016 |
Karnes J, Ross A, Schaeffer EM, Klein EA, Erho N, Yousefi K, Takhar M, Davicioni E, Trock BJ. Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients. Journal of Clinical Oncology. 34: 5056-5056. DOI: 10.1200/Jco.2016.34.15_Suppl.5056 |
0.423 |
|
| 2016 |
Karnes J, Ashab HA, Trock BJ, Ross A, Tsai H, Tosoian JJ, Alshalalfa M, Choeurng V, Yousefi K, Haddad Z, Abdollah F, Klein EA, Nguyen PL, Feng FY, Dicker A, et al. Development and validation of genomic signature to predict ADT treatment failure. Journal of Clinical Oncology. 34: 5018-5018. DOI: 10.1200/Jco.2016.34.15_Suppl.5018 |
0.465 |
|
| 2016 |
Den R, Yousefi K, Trock BJ, Davicioni E, Tosoian JJ, Thompson DJS, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Dicker A, et al. Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk. Journal of Clinical Oncology. 34: 12-12. DOI: 10.1016/S1569-9056(16)60437-2 |
0.438 |
|
| 2016 |
Ham WS, Chalfin HJ, Feng Z, Trock BJ, Humphreys E, Epstein JI, Partin AW, Han M. Pd30-05 The Impact Of Downgrading From Biopsy Gleason Score 7 To Radical Prostatectomy Gleason Score 6 On Biochemical Recurrence The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.536 |
0.397 |
|
| 2016 |
Mamawala M, Rao K, Landis P, Epstein J, Trock B, Tosoian J, Pienta K, Carter HB. Pd08-06 Risk Prediction Tool For Grade Reclassification In Favorable-Risk Men On Active Surveillance The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2822 |
0.305 |
|
| 2016 |
Fazeli R, Mamawala M, Landis P, Wolf S, Carter HB, Trock BJ. Mp15-08 Is Psa Density Or Psa (Or Neither) Useful To Predict Biopsy Reclassification In Active Surveillance Patients? The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2532 |
0.352 |
|
| 2016 |
Cullen J, Trock B, Chen Y, Rosner I, Suzman D, Feng Z, Hurwitz L, Kuo CH, McLeod D, Eisenberger M. Mp09-17 The Natural History Of Metastasis As A Function Of Psadt In A Surgically-Treated Patient Cohort Experiencing Biochemical Relapse The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2304 |
0.305 |
|
| 2016 |
Karnes RJ, Ross A, Schaeffer E, Klein E, Erho N, Yousefi K, Takhar M, Davicioni E, Trock B. MP07-01 VALIDATION OF A GENOMIC RISK CLASSIFIER TO PREDICT PROSTATE CANCER DEATH IN HIGH RISK PATIENTS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2204 |
0.48 |
|
| 2016 |
Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Humphreys E, Partin AW, Han M. Pd42-05 Grouping Gleason Score 8 And Gleason Score 9-10 Prostate Cancer As A Single Entity Risks Losing Prognostic Information For Mortality The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1757 |
0.421 |
|
| 2015 |
Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. European Urology. PMID 26456680 DOI: 10.1016/J.Eururo.2015.09.032 |
0.489 |
|
| 2015 |
Reese AC, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance. Urology. PMID 26335496 DOI: 10.1016/J.Urology.2015.07.039 |
0.398 |
|
| 2015 |
Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 3379-85. PMID 26324359 DOI: 10.1200/Jco.2015.62.5764 |
0.471 |
|
| 2015 |
Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, ... ... Trock BJ, et al. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. PMID 26058959 DOI: 10.1016/J.Eururo.2015.05.042 |
0.46 |
|
| 2015 |
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, et al. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology. PMID 25964175 DOI: 10.1016/J.Eururo.2015.04.033 |
0.469 |
|
| 2015 |
Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. PMID 25922274 DOI: 10.1016/J.Eururo.2015.04.016 |
0.384 |
|
| 2015 |
Takahashi S, Shiraishi T, Miles N, Trock BJ, Kulkarni P, Getzenberg RH. Nanowire analysis of cancer-testis antigens as biomarkers of aggressive prostate cancer. Urology. 85: 704.e1-7. PMID 25733303 DOI: 10.1016/J.Urology.2014.12.004 |
0.471 |
|
| 2015 |
Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME. Five-year Analysis of a Multi-institutional Prospective Clinical Trial of Delayed Intervention and Surveillance for Small Renal Masses: The DISSRM Registry. European Urology. PMID 25698065 DOI: 10.1016/J.Eururo.2015.02.001 |
0.333 |
|
| 2015 |
Ball MW, Gorin MA, Bhayani SB, Rogers CG, Stifelman MD, Kaouk JH, Zargar H, Marshall S, Larson JA, Rahbar HM, Trock BJ, Pierorazio PM, Allaf ME. Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis. Urologic Oncology. 33: 112.e9-14. PMID 25499258 DOI: 10.1016/J.Urolonc.2014.11.003 |
0.32 |
|
| 2015 |
Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 121: 1414-21. PMID 25492369 DOI: 10.1002/Cncr.29147 |
0.433 |
|
| 2015 |
Dianat SS, Carter HB, Pienta KJ, Schaeffer EM, Landis PK, Epstein JI, Trock BJ, Macura KJ. Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes. Urology. 85: 147-53. PMID 25440986 DOI: 10.1016/J.Urology.2014.06.085 |
0.46 |
|
| 2015 |
Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM. Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology. 85: 155-60. PMID 25440814 DOI: 10.1016/J.Urology.2014.08.014 |
0.509 |
|
| 2015 |
Patel HD, Humphreys E, Trock BJ, Han M, Carter HB. Practice patterns and individual variability of surgeons performing radical prostatectomy at a high volume academic center. The Journal of Urology. 193: 812-9. PMID 25196659 DOI: 10.1016/J.Juro.2014.08.101 |
0.434 |
|
| 2015 |
Cohen JE, Landis P, Trock BJ, Patel HD, Ball MW, Auwaerter PG, Schaeffer E, Carter HB. Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis. The Journal of Urology. 193: 552-6. PMID 25111911 DOI: 10.1016/J.Juro.2014.08.008 |
0.319 |
|
| 2015 |
Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. European Urology. 67: 342-6. PMID 24968968 DOI: 10.1016/J.Eururo.2014.06.015 |
0.48 |
|
| 2015 |
Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. Bju International. 115: 216-22. PMID 24904995 DOI: 10.1111/Bju.12828 |
0.478 |
|
| 2015 |
Feng FY, Tomlins S, Alshalalfa M, Erho N, Yousefi K, Zhao S, Den RB, Dicker A, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Trock BJ, Demarzo A, et al. Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes. Journal of Clinical Oncology. 33: 9-9. DOI: 10.1200/Jco.2015.33.7_Suppl.9 |
0.395 |
|
| 2015 |
Choudhury S, Trock BJ, Skone RB, Nardone J, Dunyak J, Shipitsin M, Epstein JI. Evaluation of early clinical experience of a novel prognostic proteomics prostate cancer biopsy test. Journal of Clinical Oncology. 33: 88-88. DOI: 10.1200/Jco.2015.33.7_Suppl.88 |
0.465 |
|
| 2015 |
Ross A, Johnson MH, Yousefi K, Davicioni E, Fedor HL, Glavaris S, Choeurng V, Buerki C, Lam LL, Erho N, Humphreys EB, Netto GJ, Han M, Partin AW, Trock BJ, et al. Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort. Journal of Clinical Oncology. 33: 5059-5059. DOI: 10.1200/Jco.2015.33.15_Suppl.5059 |
0.4 |
|
| 2015 |
Alshalalfa M, Tomlins SA, Erho N, Yousefi K, Zhao S, Den RB, Dicker AP, Trock B, DeMarzo A, Schaeffer EM, Ross A, Klein EA, Magi-Galluzzi C, Karnes JR, Jenkins RB, et al. Abstract A1-64: Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-64 |
0.407 |
|
| 2015 |
Karnes J, Tomlins S, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den R, Dicker A, Trock B, Demarzo A, Ross A, Schaeffer E, Klein E, et al. 430 Molecular and clinical characterization of 1,577 primary prostate cancers reveal novel clinical and biological insights into subtypes European Urology Supplements. 14: e430-e430a. DOI: 10.1016/S1569-9056(15)60423-7 |
0.43 |
|
| 2015 |
Tosoian J, Mamawala M, Epstein J, Landis P, Wolf S, Trock B, Carter HB. Pd6-04 A Prospective, Longitudinal Active Surveillance Program For Favorable-Risk Prostate Cancer: Long Term Outcomes The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.799 |
0.407 |
|
| 2015 |
Tomlins S, Alshalalfa M, Erho N, Yousefi K, Zhao S, den r, dicker a, trock b, Demarzo A, Ross A, Schaeffer E, Klein E, Magi-Galluzzi C, karnes j, Jenkins R, et al. MP6-09 MOLECULAR AND CLINICAL CHARACTERIZATION OF 1,577 PRIMARY PROSTATE CANCER TUMORS REVEALS NOVEL CLINICAL AND BIOLOGICAL INSIGHTS INTO ITS SUBTYPES Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.256 |
0.424 |
|
| 2015 |
Chalfin H, Liu J, Gandhi N, Feng Z, Trock B, Frank S, Bivalacqua T. MP64-10 PERIOPERATIVE BLOOD TRANSFUSION IN BLADDER CANCER PATIENTS UNDERGOING RADICAL CYSTECTOMY IS ASSOCIATED WITH INCREASED MORBIDITY AND LENGTH OF STAY BUT NOT ADVERSE ONCOLOGIC OUTCOMES Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2321 |
0.381 |
|
| 2015 |
Tosoian J, Sundi D, Trock B, Landis P, Epstein J, Schaeffer E, Mamawala M, Carter HB. Pd34-09 Comparison Of Pathologic Outcomes In Men With Favorable-Risk Prostate Cancer Undergoing Delayed Surgery After Active Surveillance Versus Immediate Surgery The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2245 |
0.419 |
|
| 2015 |
Johnson M, Ross A, Alshalalfa M, Erho N, Yousefi K, Choerung V, Glavaris S, Fedor H, Han M, Humphreys E, Partin A, Bezerra S, Faraj S, Netto G, Trock B, et al. MP61-11 SPINK1 DEFINES A MOLECULAR SUBTYPE OF PROSTATE CANCER MEN WITH MORE RAPID PROGRESSION FROM BIOCHEMICAL RECURRENCE TO DEATH IN AN AT RISK, NATURAL HISTORY COHORT Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2192 |
0.394 |
|
| 2015 |
Ross A, Johnson M, Yousefi K, Trock B, Choeurng V, Lam L, Fedor H, Ghadessi M, Buerki C, Glavaris S, Sundi D, Tosoian J, Han M, Humphreys E, Partin A, et al. 431 Validation of the Decipher® prostate cancer classifier in intermediate to high risk men treated with radical prostatectomy but without additional therapy upon PSA rise European Urology Supplements. 14: e431. DOI: 10.1016/J.Juro.2015.02.174 |
0.496 |
|
| 2015 |
Ross A, Bezerra S, Faraj S, Yousefi K, Fedor H, Glavaris S, Han M, Partin A, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock B, Schaeffer E, Netto G. Mp53-17 Clinical Validation Of The 2005 Isup Gleason Grading System In A Cohort Of Intermediate And High Risk Men Undergoing Radical Prostatectomy The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1711 |
0.4 |
|
| 2015 |
Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Mp53-02 Is Clinical Stage T2C Prostate Cancer Intermediate Or High-Risk Disease? The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1696 |
0.463 |
|
| 2015 |
Park S, Sundi D, Feng Z, Trock B, Humphreys E, Partin A, Han M. Mp4-13 Conditional Cancer Specific Survival Following Radical Prostatectomy Depends On Preoperative Risk Classification The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.156 |
0.4 |
|
| 2015 |
Kaye D, DeWeese T, Chalfin H, Trock B, Feng Z, Han M. Mp32-06 Does The Ownership Of Radiation Oncology Services Affect Urologists' Practice Patterns For The Treatment Of Prostate Cancer? The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1402 |
0.319 |
|
| 2014 |
Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5302-10. PMID 25320374 DOI: 10.1158/1078-0432.Ccr-13-3366 |
0.413 |
|
| 2014 |
Trock BJ. Adjuvant radiation following radical prostatectomy: what are the known unknowns? European Urology. 66: 251-2. PMID 24830627 DOI: 10.1016/J.Eururo.2014.04.023 |
0.391 |
|
| 2014 |
Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Alai H, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M. Obesity and long-term survival after radical prostatectomy. The Journal of Urology. 192: 1100-4. PMID 24769031 DOI: 10.1016/J.Juro.2014.04.086 |
0.384 |
|
| 2014 |
Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. The Journal of Urology. 192: 1081-7. PMID 24747657 DOI: 10.1016/J.Juro.2014.04.013 |
0.439 |
|
| 2014 |
Trock BJ. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Current Opinion in Urology. 24: 293-302. PMID 24710054 DOI: 10.1097/Mou.0000000000000050 |
0.48 |
|
| 2014 |
Kryvenko ON, Carter HB, Trock BJ, Epstein JI. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology. 83: 869-74. PMID 24680457 DOI: 10.1016/J.Urology.2013.12.054 |
0.46 |
|
| 2014 |
Gorin MA, Chalfin HJ, Epstein JI, Feng Z, Partin AW, Trock BJ. Predicting the risk of non-organ-confined prostate cancer when perineural invasion is found on biopsy. Urology. 83: 1117-21. PMID 24655556 DOI: 10.1016/J.Urology.2013.12.042 |
0.513 |
|
| 2014 |
Chalfin HJ, Frank SM, Feng Z, Trock BJ, Drake CG, Partin AW, Humphreys E, Ness PM, Jeong BC, Lee SB, Han M. Allogeneic versus autologous blood transfusion and survival after radical prostatectomy. Transfusion. 54: 2168-74. PMID 24601996 DOI: 10.1111/Trf.12611 |
0.473 |
|
| 2014 |
Tan M, Shao C, Bishop JA, Feng Z, Trock BJ, Westra WH, Ha PK. Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 150: 801-7. PMID 24493792 DOI: 10.1177/0194599814521569 |
0.331 |
|
| 2014 |
Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. Modeling grade progression in an active surveillance study. Statistics in Medicine. 33: 930-9. PMID 24123208 DOI: 10.1002/Sim.6003 |
0.448 |
|
| 2014 |
Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, Sfanos KS. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. The Prostate. 74: 61-9. PMID 24115205 DOI: 10.1002/Pros.22730 |
0.477 |
|
| 2014 |
Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. The Journal of Urology. 191: 629-37. PMID 24060641 DOI: 10.1016/J.Juro.2013.09.029 |
0.498 |
|
| 2014 |
Trock BJ, Jenkins RB, Said JW, Fine S, Knudsen B, Fedor HL, Gurel B, Lotan TL, De Marzo AM. Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance. Journal of Clinical Oncology. 32: 93-93. DOI: 10.1200/Jco.2014.32.4_Suppl.93 |
0.344 |
|
| 2014 |
Gorin M, Lotan T, Trock B, Platz E, Humphreys E, De Marzo A, Netto G, Chaux A, Han M. MP79-16 PTEN EXPRESSION LOSS IS ASSOCIATED WITH AN INCREASED RISK OF CANCER-SPECIFIC MORTALITY AMONG MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2519 |
0.424 |
|
| 2014 |
Trock BJ, Jenkins RB, Said JW, Fine S, Knudsen B, Fedor HL, Gurel B, Lotan TL, De Marzo AM. MP79-09 CHROMOSOME 8 ALTERATIONS AND PTEN LOSS IN GLEASON GRADE 3 CORES PREDICT THE PRESENCE OF UNSAMPLED GRADE 4 TUMOR: IMPLICATIONS FOR ACTIVE SURVEILLANCE Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2512 |
0.456 |
|
| 2014 |
Park SW, Jeong BC, Trock BJ, Humphreys E, Partin AW, Han M. Mp70-07 The Effect Of Additional Pathologic Features On Cancer Specific Survival Following Radical Prostatectomy In Men With Seminal Vesicle Invasion The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2206 |
0.333 |
|
| 2014 |
Hyndman ME, Bivalacqua TJ, Feng Z, Mettee LZ, Su L, Trock BJ, Pavlovich CP. Mp58-11 Nightly Sildenafil Use After Radical Prostatectomy Has Adverse Effects On Urinary Convalescence: Results From A Randomized Trial Of Nightly Vs On-Demand Dosing Regimens The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1827 |
0.344 |
|
| 2014 |
Sundi D, Kryvenko O, Epstein J, Trock B, Landis P, Feng Z, Ross A, Carter HB, Schaeffer E. MP51-05 RECLASSIFICATION RATES ARE HIGHER AMONG AFRICAN AMERICAN MEN THAN WHITE MEN ON ACTIVE SURVEILLANCE Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1661 |
0.318 |
|
| 2014 |
Kates M, Tosoian J, Trock B, Feng Z, Carter B, Partin A. Mp46-09 Indications For Intervention During Active Surveillance Of Prostate Cancer: A Comparison Of The Johns Hopkins And Prias Protocols The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1442 |
0.426 |
|
| 2013 |
Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. The Prostate. 73: 1673-80. PMID 24019101 DOI: 10.1002/Pros.22702 |
0.456 |
|
| 2013 |
Sundi D, Reese AC, Mettee LZ, Trock BJ, Pavlovich CP. Laparoscopic and robotic radical prostatectomy outcomes in obese and extremely obese men. Urology. 82: 600-5. PMID 23859532 DOI: 10.1016/J.Urology.2013.05.013 |
0.354 |
|
| 2013 |
Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. The Journal of Urology. 190: 1218-22. PMID 23643603 DOI: 10.1016/J.Juro.2013.04.071 |
0.478 |
|
| 2013 |
González-Roibón N, Han JS, Lee S, Feng Z, Arslankoz S, Smith N, Pierorazio PM, Humphreys E, Deweese TL, Partin AW, Bivalacqua TJ, Han M, Trock B, Netto GJ. Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancer. International Journal of Surgical Pathology. 21: 352-7. PMID 23564700 DOI: 10.1177/1066896913482729 |
0.422 |
|
| 2013 |
Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, ... ... Trock BJ, et al. Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology/Hematology. 85: 295-302. PMID 22878262 DOI: 10.1016/J.Critrevonc.2012.07.005 |
0.427 |
|
| 2013 |
Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, Epstein JI, Walsh PC, Trock BJ, Partin AW. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. Bju International. 111: 22-9. PMID 22834909 DOI: 10.1111/J.1464-410X.2012.11324.X |
0.507 |
|
| 2013 |
Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, Epstein JI, Walsh PC, Trock BJ, Partin AW. Erratum: An updated prostate cancer staging nomogram (partin tables) based on cases from 2006 to 2011 (BJU International 111 (22-29)) Bjui. 111. DOI: 10.1111/J.1464-410X.2013.11126.X |
0.449 |
|
| 2013 |
Takahashi S, Shiraishi T, Trock B, Kulkarni P, Getzenberg R, Tominaga T, Homma Y. 1048 CSAG4 and NOL4 are novel biomarkers to indicate aggressiveness of prostate cancer European Urology Supplements. 12: e1048. DOI: 10.1016/S1569-9056(13)61524-9 |
0.468 |
|
| 2013 |
Jeong BC, Lee SB, Feng Z, Epstein J, Trock B, Partin A, Humphreys E, Walsh P, Han M. 367 Long-Term Survival Outcome In Men With Focal Versus Established Extraprostatic Extension In A Large Radical Prostatectomy Series The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1755 |
0.446 |
|
| 2012 |
Trock BJ, Feng Z, Landis P, Carter B. Diet, supplements, and lifestyle factors and risk of progression in contemporary active surveillance patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 138. PMID 27968160 DOI: 10.1200/Jco.2012.30.5_Suppl.138 |
0.455 |
|
| 2012 |
Han M, Chang D, Kim C, Lee BJ, Zuo Y, Kim HJ, Petrisor D, Trock B, Partin AW, Rodriguez R, Carter HB, Allaf M, Kim J, Stoianovici D. Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. The Journal of Urology. 188: 2404-9. PMID 23088974 DOI: 10.1016/J.Juro.2012.07.107 |
0.447 |
|
| 2012 |
Anusionwu I, Baradaran N, Trock BJ, Stec AA, Gearhart JP, Wright EJ. Is pelvic osteotomy associated with lower risk of pelvic organ prolapse in postpubertal females with classic bladder exstrophy? The Journal of Urology. 188: 2343-6. PMID 23088967 DOI: 10.1016/J.Juro.2012.08.034 |
0.304 |
|
| 2012 |
Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. The Journal of Urology. 188: 2219-24. PMID 23083655 DOI: 10.1016/J.Juro.2012.08.028 |
0.5 |
|
| 2012 |
Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI. Gleason score 6 adenocarcinoma: should it be labeled as cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4294-6. PMID 23032616 DOI: 10.1200/Jco.2012.44.0586 |
0.485 |
|
| 2012 |
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5471-8. PMID 23008476 DOI: 10.1158/1078-0432.Ccr-12-1502 |
0.506 |
|
| 2012 |
Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ. Association of (2)proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer The Journal of Urology. 188: 1131-1136. PMID 22901577 DOI: 10.1016/J.Juro.2012.06.009 |
0.485 |
|
| 2012 |
Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M. Causes of death after radical prostatectomy at a large tertiary center. The Journal of Urology. 188: 798-801. PMID 22819416 DOI: 10.1016/J.Juro.2012.04.109 |
0.441 |
|
| 2012 |
Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, Humphreys E, Han M. Impact of surgical margin status on prostate-cancer-specific mortality. Bju International. 110: 1684-9. PMID 22788795 DOI: 10.1111/J.1464-410X.2012.11371.X |
0.516 |
|
| 2012 |
Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. European Urology. 61: 1019-24. PMID 22336380 DOI: 10.1016/J.Eururo.2012.01.050 |
0.441 |
|
| 2012 |
Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. Bju International. 110: 651-7. PMID 22289613 DOI: 10.1111/J.1464-410X.2011.10875.X |
0.508 |
|
| 2012 |
Trock BJ. Re: Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease: N. D. Arvold, M. H. Chen, J. W. Moul, B. J. Moran, D. E. Dosoretz, L. L. Bañez, M. J. Katin, M. H. Braccioforte and A. V. D'Amico J Urol 2011; 186: 91-96. The Journal of Urology. 187: 356; author reply 35. PMID 22119358 DOI: 10.1016/J.Juro.2011.09.014 |
0.326 |
|
| 2012 |
Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, Klein EA, Jones JS, Wang S, McAskill T, Mehrotra J, Raghavan B, Partin AW. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. Bju International. 110: 56-62. PMID 22077694 DOI: 10.1111/J.1464-410X.2011.10718.X |
0.475 |
|
| 2012 |
Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. Bju International. 109: 898-905. PMID 21933328 DOI: 10.1111/J.1464-410X.2011.10551.X |
0.349 |
|
| 2012 |
Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. Bju International. 109: 32-9. PMID 21777360 DOI: 10.1111/J.1464-410X.2011.10422.X |
0.503 |
|
| 2012 |
Sidana A, Hernandez DJ, Feng Z, Partin AW, Trock BJ, Saha S, Epstein JI. Treatment decision-making for localized prostate cancer: what younger men choose and why. The Prostate. 72: 58-64. PMID 21520163 DOI: 10.1002/Pros.21406 |
0.413 |
|
| 2012 |
Sundi D, Reese AC, Trock BJ, Mettee LZ, Pavlovich CP. 509 Outcomes Of Radical Prostatectomy In Very Obese Men Using An Extraperitoneal Minimally-Invasive Approach The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.580 |
0.309 |
|
| 2012 |
Mullins J, Hyams E, Pierorazio P, Feng Z, Trock B, Allaf M, Matlaga B. 502 The Impact Of Surgeon Volume And Surgical Approach On Post-Radical Prostatectomy Morbidity In Maryland Hospitals The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.573 |
0.356 |
|
| 2012 |
Anusionwu I, Baradaran N, Trock B, Stec A, Gearhart J, Wright EJ. 1614 Is Pelvic Osteotomy Associated With Lower Risk Of Pelvic Organ Prolapse In Patients With Classic Bladder Exstrophy The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1409 |
0.304 |
|
| 2011 |
Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, Walsh PC. Can PSA testing stop 10 years after radical prostatectomy? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 179. PMID 27968444 DOI: 10.1200/Jco.2011.29.7_Suppl.179 |
0.404 |
|
| 2011 |
Loeb S, Trock BJ. Re: randomised prostate cancer screening trial: 20 year follow-up. European Urology. 60: 1306-7. PMID 22054407 DOI: 10.1016/J.Eururo.2011.08.070 |
0.437 |
|
| 2011 |
Trock BJ. Application of metabolomics to prostate cancer. Urologic Oncology. 29: 572-81. PMID 21930089 DOI: 10.1016/J.Urolonc.2011.08.002 |
0.461 |
|
| 2011 |
Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg RH. Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. Journal of Translational Medicine. 9: 153. PMID 21917134 DOI: 10.1186/1479-5876-9-153 |
0.504 |
|
| 2011 |
Karram S, Trock BJ, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. The American Journal of Surgical Pathology. 35: 1351-5. PMID 21836493 DOI: 10.1097/Pas.0B013E3182217B79 |
0.486 |
|
| 2011 |
Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, Walsh PC. Can we stop prostate specific antigen testing 10 years after radical prostatectomy? The Journal of Urology. 186: 500-5. PMID 21679999 DOI: 10.1016/J.Juro.2011.03.116 |
0.46 |
|
| 2011 |
Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2185-90. PMID 21464416 DOI: 10.1200/Jco.2010.32.8112 |
0.496 |
|
| 2011 |
Eifler JB, Levinson AW, Hyndman ME, Trock BJ, Pavlovich CP. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy Journal of Urology. 185: 1661-1665. PMID 21419428 DOI: 10.1016/J.Juro.2010.12.044 |
0.308 |
|
| 2011 |
Lin BM, Hyndman ME, Steele KE, Feng Z, Trock BJ, Schweitzer MA, Pavlovich CP. Incidence and risk factors for inguinal and incisional hernia after laparoscopic radical prostatectomy. Urology. 77: 957-62. PMID 21333335 DOI: 10.1016/J.Urology.2010.12.011 |
0.365 |
|
| 2011 |
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. The Journal of Urology. 185: 869-75. PMID 21239008 DOI: 10.1016/J.Juro.2010.10.057 |
0.475 |
|
| 2011 |
Trock BJ, Walsh PC. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 117: 656; author reply 65. PMID 20922793 DOI: 10.1002/Cncr.25407 |
0.42 |
|
| 2011 |
Karram S, Trock B, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy?correlation with radical prostatectomy findings International Braz J Urol. 37: 668-668. DOI: 10.1590/S1677-55382011000500022 |
0.463 |
|
| 2011 |
Sidana A, Hernandez D, Feng Z, Partin A, Trock B, Saha S, Epstein J. Treatment decision-making for localized prostate cancer: what younger men choose and why International Braz J Urol. 37: 406-407. DOI: 10.1590/S1677-55382011000300022 |
0.435 |
|
| 2011 |
Dinizo M, Chalfin H, Trock B, Partin A, Walsh P, Humphreys E, Han M. 192 Implications Of Surgical Margin Status On Prostate Cancer-Specific Survival The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.262 |
0.485 |
|
| 2011 |
Tosoian J, Isharwal S, Feng Z, Makarov D, Landis P, Veltri R, Trock B, Epstein J, Partin A, Sokoll L, Carter HB, Loeb S. 2323 [-2]Propsa Predicts Biopsy Reclassification In Men On Active Surveillance For Prostate Cancer The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2570 |
0.482 |
|
| 2011 |
Ross AE, Zhaoyong F, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM. 1638 Effects Of 5-Alpha Reductase Inhibitor Use In Monitored Men With Very-Low Risk Prostate Cancer The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1747 |
0.442 |
|
| 2010 |
Han M, Trock BJ, Partin AW, Humphreys EB, Bivalacqua TJ, Guzzo TJ, Walsh PC. The impact of preoperative erectile dysfunction on survival after radical prostatectomy. Bju International. 106: 1612-7. PMID 20590546 DOI: 10.1111/J.1464-410X.2010.09472.X |
0.33 |
|
| 2010 |
Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S, Carter HB. Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer. Bju International. 106: 1284-90; discussion . PMID 20477823 DOI: 10.1111/J.1464-410X.2010.09363.X |
0.463 |
|
| 2010 |
Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB. Risk stratification of men choosing surveillance for low risk prostate cancer. The Journal of Urology. 183: 1779-85. PMID 20304433 DOI: 10.1016/J.Juro.2010.01.001 |
0.507 |
|
| 2010 |
Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 76: 710-4. PMID 19931898 DOI: 10.1016/J.Urology.2009.09.014 |
0.526 |
|
| 2010 |
Zhou J, Trock B, Tsangaris TN, Friedman NB, Shapiro D, Brotzman M, Chan-Li Y, Chan DW, Li J. A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. Breast Cancer Research and Treatment. 123: 73-86. PMID 19902353 DOI: 10.1007/S10549-009-0625-5 |
0.311 |
|
| 2010 |
Trock BJ, Feng Z, Landis P, Epstein JI, Carter B. Surgical outcomes and implications for cure in active surveillance patients who undergo delayed radical prostatectomy. Journal of Clinical Oncology. 28: 4506-4506. DOI: 10.1200/Jco.2010.28.15_Suppl.4506 |
0.469 |
|
| 2010 |
Sidana A, Trock B, Feng Z, Hernandez D, Epstein J. Abstract LB-435: Treatment decision-making for clinically localized Gleason score 6 prostate cancer: What younger men choose and why Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-435 |
0.389 |
|
| 2010 |
Agurs-Collins TD, Makambi K, Seung H, Trock BJ, Cullen KJ. Abstract A78: Associations between IGF-axis, testosterone and nutrients in healthy African American and Caucasian men at increased risk for prostate cancer Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A78 |
0.454 |
|
| 2010 |
Loeb S, Ross AE, Allaf ME, Feng Z, Trock BJ, Walsh PC. 290 CAN WE STOP PSA TESTING 10 YEARS AFTER RADICAL PROSTATECTOMY? Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.352 |
0.338 |
|
| 2010 |
Trock BJ, Feng Z, Landis P, Epstein JI, Carter HB. 1062 Pathologic Stage And Implications For Cure In Active Surveillance Patients Who Undergo Radical Prostatectomy The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.2186 |
0.329 |
|
| 2010 |
Tosoian J, Trock B, Landis P, Feng Z, Epstein J, Partin A, Walsh P, Carter H. 933 Psa Free Outcomes After Radical Prostatectomy Among Men Initially Managed With Active Surveillance For Prostate Cancer: Johns Hopkins Experience The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1749 |
0.475 |
|
| 2009 |
Trock B, Han M, Humphreys EB, Partin AW, Eisenberger MA, Walsh PC. Survival following early hormone therapy for men with rapid PSA doubling time within 2 years following radical prostatectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5065. PMID 27964253 DOI: 10.1200/Jco.2009.27.15_Suppl.5065 |
0.361 |
|
| 2009 |
Stephenson AJ, Klein EA, Kattan MW, Han M, Partin AW, Walsh PC, Trock BJ, Wood DP, Eggener SE, Eastham JA, Scardino PT. Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5007. PMID 27962891 DOI: 10.1200/Jco.2009.27.15_Suppl.5007 |
0.489 |
|
| 2009 |
Antonarakis ES, Trock BJ, Feng Z, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5008. PMID 27962890 DOI: 10.1200/Jco.2009.27.15_Suppl.5008 |
0.491 |
|
| 2009 |
Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. The Journal of Urology. 182: 1364-70. PMID 19683280 DOI: 10.1016/J.Juro.2009.06.048 |
0.427 |
|
| 2009 |
Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. The Journal of Urology. 182: 491-6; discussion 49. PMID 19524974 DOI: 10.1016/J.Juro.2009.04.007 |
0.463 |
|
| 2009 |
Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. The Prostate. 69: 1195-205. PMID 19434657 DOI: 10.1002/Pros.20970 |
0.461 |
|
| 2009 |
Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, Metter EJ. Prostate specific antigen testing among the elderly--when to stop? The Journal of Urology. 181: 1606-14; discussion . PMID 19246059 DOI: 10.1016/J.Juro.2008.11.117 |
0.487 |
|
| 2009 |
Yang L, Gaikwad NW, Meza J, Cavalieri EL, Muti P, Trock B, Rogan EG. Novel biomarkers for risk of prostate cancer: results from a case-control study. The Prostate. 69: 41-8. PMID 18816637 DOI: 10.1002/Pros.20850 |
0.418 |
|
| 2009 |
Roberts WB, Tavora F, Trock BJ, Epstein JI, Walsh PC. Safety And Feasibility Of Nerve-Sparing During Radical Prostatectomy In Men With Multiple Biopsy Cores Of Gleason 6 The Journal of Urology. 181: 719-720. DOI: 10.1016/S0022-5347(09)62008-5 |
0.339 |
|
| 2009 |
Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body Mass Index And Prostate-Specific Antigen As A Predictor Of Adverse Pathology And Biochemical Recurrence Following Radical Prostatectomy The Journal of Urology. 181: 574. DOI: 10.1016/S0022-5347(09)61619-0 |
0.428 |
|
| 2009 |
Trock BJ, Han M, Freedland SJ, Humphreys EB, Partin AW, Walsh PC. Impact Of Salvage Androgen Deprivation Therapy On Overall Survival In Men With Biochemical Recurrence After Radical Prostatectomy The Journal of Urology. 181: 458-458. DOI: 10.1016/S0022-5347(09)61299-4 |
0.381 |
|
| 2008 |
Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, Hsu FC, Wiklund F, Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5819-24. PMID 18794092 DOI: 10.1158/1078-0432.Ccr-08-0934 |
0.473 |
|
| 2008 |
Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Hsu FC, Kim ST, Liu W, Zhu Y, Stattin P, Adami HO, Wiley KE, Dimitrov L, Sun J, ... ... Trock BJ, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nature Genetics. 40: 1153-5. PMID 18758462 DOI: 10.1038/Ng.214 |
0.354 |
|
| 2008 |
Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, Raj MH, Rao PN. Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells. Journal of Biomedicine & Biotechnology. 2008: 163902. PMID 18584049 DOI: 10.1155/2008/163902 |
0.421 |
|
| 2008 |
Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Jama. 299: 2760-9. PMID 18560003 DOI: 10.1001/Jama.299.23.2760 |
0.488 |
|
| 2008 |
Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD, Trock BJ, Partin AW, Walsh PC, Grönberg H, Xu J, Isaacs WB, Zheng SL. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. The Prostate. 68: 1257-62. PMID 18491292 DOI: 10.1002/Pros.20793 |
0.445 |
|
| 2008 |
Trock BJ. A clinician's guide to statistical methods in urologic oncology. Urologic Oncology. 26: 299. PMID 18452824 DOI: 10.1016/J.Urolonc.2008.02.014 |
0.35 |
|
| 2008 |
Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology. 72: 1246-51. PMID 18387658 DOI: 10.1016/J.Urology.2008.01.052 |
0.454 |
|
| 2008 |
Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. The Journal of Urology. 179: 1780-4; discussion 1. PMID 18343439 DOI: 10.1016/J.Juro.2008.01.032 |
0.472 |
|
| 2008 |
Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology. 72: 172-6. PMID 18304619 DOI: 10.1016/J.Urology.2007.10.055 |
0.524 |
|
| 2008 |
Pavlovich CP, Trock BJ, Sulman A, Wagner AA, Mettee LZ, Su LM. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States. The Journal of Urology. 179: 917-21; discussion 9. PMID 18207191 DOI: 10.1016/J.Juro.2007.10.067 |
0.463 |
|
| 2008 |
Hoque MO, Begum S, Brait M, Jeronimo C, Zahurak M, Ostrow KL, Rosenbaum E, Trock B, Westra WH, Schoenberg M, Goodman SN, Sidransky D. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer Journal of Urology. 179: 743-747. PMID 18082200 DOI: 10.1016/J.Juro.2007.09.019 |
0.336 |
|
| 2008 |
Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC, Trock BJ. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. The Journal of Urology. 179: 156-61; discussion 1. PMID 18001801 DOI: 10.1016/J.Juro.2007.08.133 |
0.5 |
|
| 2008 |
Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate Cancer-Specific Survival Following Salvage Radiotherapy Vs. Observation In Men With Biochemical Recurrence After Radical Prostatectomy The Journal of Urology. 179: 491-492. DOI: 10.1016/S0022-5347(08)61447-0 |
0.5 |
|
| 2008 |
Trock BJ, Guo CC, Tamas EF, Epstein JI. Prognostic Significance Of Positive Surgical Margins In Radical Prostatectomies: An Analysis Based On Their Anatomic Locations The Journal of Urology. 179: 197-197. DOI: 10.1016/S0022-5347(08)60572-8 |
0.317 |
|
| 2008 |
Trock BJ, DeWeese TL. Adjuvant radiotherapy after surgery for prostate cancer - Reply Jama - Journal of the American Medical Association. 300: 2119. DOI: 10.1001/Jama.2008.563 |
0.453 |
|
| 2007 |
Nielsen ME, Bastian PJ, Palapattu GS, Trock BJ, Schoenberg MP, Chan T, Rogers CG. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection. Urology. 70: 1091-5. PMID 18158024 DOI: 10.1016/J.Urology.2007.08.044 |
0.353 |
|
| 2007 |
Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. The Journal of Urology. 179: 529-535. PMID 18076941 DOI: 10.1016/J.Juro.2007.09.038 |
0.498 |
|
| 2007 |
Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Bälter K, ... ... Trock BJ, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Journal of the National Cancer Institute. 99: 1836-44. PMID 18073375 DOI: 10.1093/Jnci/Djm250 |
0.455 |
|
| 2007 |
Wagner AA, Link RE, Trock BJ, Sullivan W, Pavlovich CP. Comparison of open and laparoscopic radical prostatectomy outcomes from a surgeon's early experience. Urology. 70: 667-71. PMID 17991534 DOI: 10.1016/J.Urology.2007.06.1104 |
0.378 |
|
| 2007 |
Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageot J, ... ... Trock BJ, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. Journal of the National Cancer Institute. 99: 1525-33. PMID 17925536 DOI: 10.1093/Jnci/Djm169 |
0.42 |
|
| 2007 |
Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy Clinical Cancer Research. 13: 5361-5367. PMID 17875764 DOI: 10.1158/1078-0432.Ccr-06-2781 |
0.463 |
|
| 2007 |
Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML. Impact of patient age on biochemical recurrence rates following radical prostatectomy. The Journal of Urology. 178: 1933-7; discussion 1. PMID 17868723 DOI: 10.1016/J.Juro.2007.07.016 |
0.492 |
|
| 2007 |
Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, Gonzalgo ML. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. The Journal of Urology. 178: 1311-5. PMID 17698095 DOI: 10.1016/J.Juro.2007.05.143 |
0.439 |
|
| 2007 |
Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 69: 1095-101. PMID 17572194 DOI: 10.1016/J.Urology.2007.03.042 |
0.463 |
|
| 2007 |
Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. EPCA-2: a highly specific serum marker for prostate cancer. Urology. 69: 714-20. PMID 17445657 DOI: 10.1016/J.Urology.2007.01.097 |
0.469 |
|
| 2007 |
Parsons JK, Partin AW, Trock B, Bruzek DJ, Cheli C, Sokoll LJ. Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy. Bjui. 99: 758-761. PMID 17378839 DOI: 10.1111/J.1464-410X.2007.06680.X |
0.427 |
|
| 2007 |
Carter HB, Ferrucci L, Kettermann A, Landis P, Wright J, Epstein JI, Trock BJ, Metter EJ. Response: Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability [5] Journal of the National Cancer Institute. 99: 490. DOI: 10.1093/jnci/djk101 |
0.343 |
|
| 2007 |
Han M, Humphreys EB, Partin AW, Trock BJ, Agro MJ, Walsh PC. 394: Overall Survival of men Undergoing Radical Prostatectomy The Journal of Urology. 177: 131-131. DOI: 10.1016/S0022-5347(18)30647-5 |
0.37 |
|
| 2007 |
Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. 332: Updated Nomogram to Predict Pathologic stage of Prostate Cancer Given PSA, Clinical stage, and Biopsy Gleason Score (Partin Tables) Based on Cases From 2000-2005 The Journal of Urology. 177: 112-112. DOI: 10.1016/S0022-5347(18)30597-4 |
0.445 |
|
| 2006 |
Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability Journal of the National Cancer Institute. 98: 1521-1527. PMID 17077354 DOI: 10.1093/Jnci/Djj410 |
0.494 |
|
| 2006 |
Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R. Potential biomarker for early risk assessment of prostate cancer Prostate. 66: 1565-1571. PMID 16894534 DOI: 10.1002/Pros.20484 |
0.449 |
|
| 2006 |
Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. Journal of the National Cancer Institute. 98: 459-71. PMID 16595782 DOI: 10.1093/Jnci/Djj102 |
0.329 |
|
| 2006 |
Rais-Bahrami S, Lima GC, Varkarakis IM, Romero FR, Trock B, Jarrett TW, Kavoussi LR. Intraoperative Conversion of Laparoscopic Partial Nephrectomy Journal of Endourology. 20: 205-208. PMID 16548731 DOI: 10.1089/End.2006.20.205 |
0.309 |
|
| 2006 |
Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome Journal of the National Cancer Institute. 98: 355-357. PMID 16507832 DOI: 10.1093/Jnci/Djj072 |
0.49 |
|
| 2006 |
Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, Partin AW. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate Urology. 67: 115-119. PMID 16413345 DOI: 10.1016/J.Urology.2005.07.037 |
0.476 |
|
| 2006 |
Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC. Factors influencing prostate cancer specific mortality in patients receiving delayed androgen deprivation therapy for metastasis after biochemical recurrence following radical prostatectomy Journal of Clinical Oncology. 24: 4571-4571. DOI: 10.1200/Jco.2006.24.18_Suppl.4571 |
0.487 |
|
| 2006 |
Sulman A, Su L, Trock BJ, Wagner AA, Mettee L, Pavlovich CP. 1146: Laparoscopic Radical Prostatectomy: Interim Analysis of Oncologic Outcomes Following a 4 Year Experience The Journal of Urology. 175: 368-368. DOI: 10.1016/S0022-5347(18)33371-8 |
0.309 |
|
| 2006 |
Bastian PJ, Palapattu GS, Rogers CG, Lin X, Yegnasubramanian S, Mangold LA, Trock BJ, Eisenberger MA, Partin AW, Nelson WG. 849: Preoperative Serum Concentration of Cell-Free Circulating Cancer DNA in Patients with Prostate Cancer and the Risk of Recurrence after Radical Prostatectomy The Journal of Urology. 175: 274-274. DOI: 10.1016/S0022-5347(18)33085-4 |
0.469 |
|
| 2005 |
Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC, Terris MK. Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy Clinical Cancer Research. 11: 7735-7742. PMID 16278394 DOI: 10.1158/1078-0432.Ccr-04-0785 |
0.44 |
|
| 2005 |
Gonzalgo ML, Pavlovich CP, Trock BJ, Link RE, Sullivan W, Su LM. Classification and trends of perioperative morbidities following laparoscopic radical prostatectomy Journal of Urology. 174: 135-139. PMID 15947598 DOI: 10.1097/01.Ju.0000161607.04334.26 |
0.367 |
|
| 2005 |
Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clinical Cancer Research. 11: 4037-4043. PMID 15930338 DOI: 10.1158/1078-0432.Ccr-04-2446 |
0.502 |
|
| 2005 |
Ellison LM, Trock BJ, Poe NR, Partin AW. The effect of hospital volume on cancer control after radical prostatectomy Journal of Urology. 173: 2094-2098. PMID 15879850 DOI: 10.1097/01.Ju.0000158156.80315.Fe |
0.469 |
|
| 2005 |
Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. The Journal of Urology. 173: 450-3. PMID 15643200 DOI: 10.1097/01.Ju.0000151370.82099.1A |
0.521 |
|
| 2005 |
Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC. Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? Journal of Urology. 173: 446-449. PMID 15643199 DOI: 10.1097/01.Ju.0000151135.80249.C9 |
0.381 |
|
| 2005 |
Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock BJ, Eisenberger MA, Partin AW, Nelson WG. 624Preoperative serum GSTP1 CPG island hypermethylation predicts the risk of early PSA recurrence following radical prostatectomy European Urology Supplements. 4: 158. DOI: 10.1016/S1569-9056(05)80628-1 |
0.372 |
|
| 2005 |
Trock BJ, Tsuzuki T, Aydin H, Hernandez D, Walsh PC, Epstein JI. 1601: Different Gleason Scores in the Same Lobe: A Novel New Marker to Predict Side-Specific Extraprostatic Extension in Prostate Cancer Patients with Biopsy Gleason 7 or Higher The Journal of Urology. 173: 433-433. DOI: 10.1016/S0022-5347(18)35723-9 |
0.475 |
|
| 2005 |
Parsons JK, Sokoll LJ, Trock BJ, Bruzek DJ, Cheli CD, Partin AW. 957: Validity of Complexed Prostate Specific Antigen (CPSA) for the Diagnosis of Biochemical Recurrence after Radical Retropubic Prostatectomy The Journal of Urology. 173: 259-259. DOI: 10.1016/S0022-5347(18)35113-9 |
0.435 |
|
| 2005 |
Trock BJ. Screening with prostate specific antigen and metastatic prostate cancer risk: Population based case-control study: Editorial comment Journal of Urology. 174: 499. |
0.361 |
|
| 2004 |
Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, Hayes DF. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8332-40. PMID 15623610 DOI: 10.1158/1078-0432.Ccr-04-0297 |
0.32 |
|
| 2004 |
Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: Results of long-term followup Journal of Urology. 172: 1860-1864. PMID 15540739 DOI: 10.1097/01.Ju.0000139886.25848.4A |
0.434 |
|
| 2004 |
Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer Journal of Urology. 172: 1840-1844. PMID 15540734 DOI: 10.1097/01.Ju.0000140912.45821.1D |
0.301 |
|
| 2004 |
Palapattu GS, Haisfield-Wolfe ME, Walker JM, BrintzenhofeSzoc K, Trock B, Zabora J, Schoenberg M. Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. The Journal of Urology. 172: 1814-7. PMID 15540727 DOI: 10.1097/01.Ju.0000141245.08456.1A |
0.379 |
|
| 2004 |
Palapattu GS, Bastian PJ, Slavney PR, Haisfield-Wolfe ME, Walker JM, Brintzenhofeszoc K, Trock B, Zabora J, Schoenberg MP. Preoperative somatic symptoms are associated with disease progression in patients with bladder carcinoma after cystectomy. Cancer. 101: 2209-13. PMID 15476276 DOI: 10.1002/Cncr.20639 |
0.338 |
|
| 2004 |
Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC, Trock B, Amling CL. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels†‡ Cancer. 101: 748-753. PMID 15305405 DOI: 10.1002/Cncr.20390 |
0.477 |
|
| 2004 |
Freedland SJ, Terris MK, Presti JC, Amling CL, Kane CJ, Trock B, Aronson WJ. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. The Journal of Urology. 172: 520-524. PMID 15247719 DOI: 10.1097/01.Ju.0000135302.58378.Ae |
0.387 |
|
| 2004 |
Freedland SJ, Aronson WJ, JCPJ, Amling CL, Terris MK, Trock B, Kane CJ. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 100: 1633-1638. PMID 15073850 DOI: 10.1002/Cncr.20122 |
0.459 |
|
| 2004 |
Trock BJ, Brotzman M, Utz WJ, Ugarte RR, Kaplan SA, Larson TR, Blute ML, Roehrborn CG, Partin AW. Long-Term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia: Results at three months through four years Urology. 63: 716-721. PMID 15072887 DOI: 10.1016/J.Urology.2003.11.006 |
0.343 |
|
| 2003 |
Gonzalgo ML, Brotzman M, Trock BJ, Geringer AM, Burnett AL, Jarow JP. Clinical efficacy of sildenafil citrate and predictors of long-term response Journal of Urology. 170: 503-506. PMID 12853809 DOI: 10.1097/01.Ju.0000071478.69480.Fd |
0.342 |
|
| 2003 |
Liang W, Lawrence WF, Burnett CB, Hwang YT, Freedman M, Trock BJ, Mandelblatt JS, Lippman ME. Acceptability of diagnostic tests for breast cancer. Breast Cancer Research and Treatment. 79: 199-206. PMID 12825854 DOI: 10.1023/A:1023914612152 |
0.3 |
|
| 2002 |
Gretzer MB, Trock BJ, Han M, Walsh PC. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria Journal of Urology. 168: 1419-1422. PMID 12352408 DOI: 10.1016/S0022-5347(05)64464-3 |
0.364 |
|
| 2001 |
Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Disease Markers. 17: 301-7. PMID 11790897 DOI: 10.1155/2001/674959 |
0.319 |
|
| 2001 |
Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, Partin AW. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Urology. 58: 746-751. PMID 11711353 DOI: 10.1016/S0090-4295(01)01336-X |
0.459 |
|
| 2001 |
Davidson BJ, Root WA, Trock BJ. Age and survival from squamous cell carcinoma of the oral tongue Head and Neck. 23: 273-279. PMID 11400227 DOI: 10.1002/Hed.1030 |
0.35 |
|
| 2001 |
Trock BJ. Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials Urology. 57: 241-247. PMID 11295636 DOI: 10.1016/S0090-4295(00)00983-3 |
0.456 |
|
| 2000 |
Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance British Journal of Cancer. 83: 1688-1695. PMID 11104567 DOI: 10.1054/Bjoc.2000.1522 |
0.316 |
|
| 1998 |
Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Research and Treatment. 52: 305-319. PMID 10066089 DOI: 10.1023/A:1006197805041 |
0.315 |
|
| 1998 |
Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rusmussen AA, Montogomery EA, Bischoff EK, Hanigan MH, Cullen KJ. Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer Chemico-Biological Interactions. 111: 187-198. PMID 9679554 DOI: 10.1016/S0009-2797(97)00161-0 |
0.302 |
|
| 1996 |
Trock BJ. Breast cancer in African American women: Epidemiology and tumor biology Breast Cancer Research and Treatment. 40: 11-24. PMID 8888149 DOI: 10.1007/Bf01805999 |
0.311 |
|
| 1996 |
Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, Halpern AC. A Prognostic Model for Predicting 10-Year Survival in Patients with Primary Melanoma Annals of Internal Medicine. 125: 369-375. PMID 8702087 DOI: 10.7326/0003-4819-125-5-199609010-00003 |
0.331 |
|
| 1996 |
Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes Journal of the American Medical Association. 275: 1885-1892. PMID 8648868 DOI: 10.1001/Jama.275.24.1885 |
0.309 |
|
| 1996 |
Dickson RB, Low JA, Johnson MD, Hawkins MJ, Trock BJ. Blood-borne indicators of breast cancer and their use in experimental, medical oncologic, and prevention studies Breast. 5: 379-384. DOI: 10.1016/S0960-9776(96)90009-0 |
0.331 |
|
| 1995 |
Atienza DM, FACPCLVMD, Trock B, Swain SM. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer. 76: 2485-2490. PMID 8625074 DOI: 10.1002/1097-0142(19951215)76:12<2485::Aid-Cncr2820761212>3.0.Co;2-J |
0.316 |
|
| 1995 |
Trock BJ. Application of biological markers in cancer environmental epidemiology Toxicology. 101: 93-98. PMID 7631327 DOI: 10.1016/0300-483X(95)03022-8 |
0.304 |
|
| 1992 |
Trock B. Biologic markers as predictors of risk in aerodigestive tract cancers. Advances in Experimental Medicine and Biology. 320: 47-54. PMID 1279956 DOI: 10.1007/978-1-4615-3468-6_7 |
0.343 |
|
| 1990 |
Myers RE, Trock BJ, Lerman C, Wolf T, Ross E, Engstrom PF. Adherence to colorectal cancer screening in an HMO population. Preventive Medicine. 19: 502-14. PMID 2235919 DOI: 10.1016/0091-7435(90)90049-P |
0.323 |
|
| Show low-probability matches. |